DDInter1042 DDInter712
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
Famotidine {u} (Compound) binds {v} (Gene) SLC47A1
Famotidine {u} (Compound) upregulates {v} (Gene) IFNAR1
Famotidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Famotidine {u} (Compound) downregulates {v} (Gene) PCNA
Famotidine {u} (Compound) causes {v} (Side Effect) Jaundice
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Famotidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Famotidine (Compound) binds SLC47A1 (Gene)
Famotidine (Compound) upregulates IFNAR1 (Gene)
Famotidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Famotidine (Compound) downregulates PCNA (Gene)
Famotidine (Compound) causes Jaundice (Side Effect)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine
Famotidine may lead to a major life threatening interaction when taken with Dasatinib